ReviewChemistry & biodiversity2026
Isothiocyanates in Cancer Therapeutics - A Molecular Perspective.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isothiocyanates (ITCs) are naturally occurring organo-sulfur compounds. They occur widely in different plant sources, being most abundant in Brassicaceae family. Several of them have been demonstrated to possess significant bioactivities and health benefits including anticancer, anti-inflammatory, and antimicrobial activities. ITCs have very high electrophilicity and nucleophilicity due to the carbon and sulfur atom, respectively. Thus, chemical structure plays a prominent role in their bioactivities and ability to inhibit tumorigenesis. ITCs are potent against many forms of cancers and tumors. ITCs as drug conjugates and in combination therapies as antitumor therapeutic agents have shown promising prospects for clinical applications. Evaluation of possible ways to retain and/or enhance conversion of plant-derived GLSs into beneficial ITCs, can aid in enhancing nutritive and anticancer properties of ITC rich dietary plant sources. This review presents a comprehensive account of ITCs, their structure-activity relationship, specific biological functions to inhibit tumorigenesis and mechanism of action of different ITCs. Some examples on the use of ITC-drug conjugates and their use in combination therapies as promising anticancer therapeutics are highlighted. Further, methods to enhance nutritive properties through the conversion of glucosinolates (GLSs) into beneficial ITCs have also been proposed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.